Pliant Therapeutics shares are trading higher after the company announced bexotegrast met its primary and secondary endpoints in the Phase 2a liver fibrosis trial.
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics announced that bexotegrast met its primary and secondary endpoints in the Phase 2a liver fibrosis trial, leading to a rise in the company's shares.
September 26, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pliant Therapeutics' stock is trading higher after successful results from the Phase 2a liver fibrosis trial of bexotegrast.
The successful results from the Phase 2a liver fibrosis trial of bexotegrast indicate a significant milestone for Pliant Therapeutics. This positive news is likely to increase investor confidence, leading to a rise in the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100